Thomas Faitg - Concepedia

Author

Thomas Faitg

GlaxoSmithKline (United States)

Also Known As

Faitg, T., T. FAITG, T. Faitg, Thomas Faitg, Thomas H Faitg, Thomas H. Faitg

Publications

501

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United States)École Polytechnique City of Hope Laboratoire de Synthèse Organique Memorial Sloan Kettering Cancer Center

About

Thomas Faitg is an author at GlaxoSmithKline (United States) specializing in organic chemistry, chemistry, and engineering.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Engineering	3	3	91
2	Medicine	3	3	240
3	Biomolecular Engineering	2	2	56
4	Natural Sciences	1	1	204
5	Biochemistry	1	1	204

Thomas Faitg

Publications

478

Citations

H-Index

Page 1

	Year	Citations
Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction Aidan G. Gilmartin, Thomas Faitg, Mark C. Richter, Nature Chemical Biology Proteinlipid InteractionProtein FunctionSignal TransductionFlap-subdomain InteractionBiochemistry	2014	204
Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma Edward A. Stadtmauer, Thomas Faitg, Daniel E. Lowther, Blood Advances	2019	85
Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma Alexandra Gyurdieva, Stefan Zajic, Ya-Fang Chang, Nature Communications	2022	50
General access to polyhydroxylated nortropane derivatives through hetero Diels–Alder cycloadditions. Part 3: Synthesis of natural (+)-calystegine B2 Thomas Faitg, Josette Soulié, Jean‐Yves Lallemand, Tetrahedron Asymmetry DerivativesEngineeringGeneral AccessOrganic ChemistryNortropane Derivatives	1999	35
Asymmetric Isomerisation of a Cyclic Diene: a Comparative Study of BINAP and BIPNOR–Rhodium(I) Catalysts Thomas Faitg, Josette Soulié, Jean‐Yves Lallemand, Tetrahedron Chemical EngineeringEngineeringOrganic ChemistryOrganometallic CatalysisCatalysis	2000	35
General access to polyhydroxylated nortropane derivatives through hetero diels-alder cycloaddition. Part II: Synthesis of (±) calystegine B2. Josette Soulié, Thomas Faitg, Jean‐François Betzer, Tetrahedron DerivativesEngineeringGeneral AccessOrganic ChemistryCalystegine B2	1996	21
387 The Focal Adhesion Kinase Inhibitor GSK2256098: a Potent and Selective Inhibitor for the Treatment of Cancer K R Auger, Kimberly N. Smitheman, Susan Korenchuk, European Journal of Cancer Signaling PathwayMedicineCell AdhesionSelective InhibitorCancer Cell Biology	2012	20
Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial. Sandra P. D’Angelo, Andrew Furness, Fiona Thistlethwaite, Journal of Clinical Oncology Pivotal Ignyte-eso TrialSurgical OncologyImmunologyImmunoeditingPathology	2024	16
Two convenient regioselective syntheses of 1-N-alkyl-3-aryl-4-[pyrimidin-4-yl]-pyrazoles Jeffrey M. Ralph, Thomas Faitg, Domingos J. Silva, Tetrahedron Letters Organic ChemistryConvenient Regioselective SynthesesStereoselective SynthesisChemistrySynthetic Chemistry	2009	12

Page 1